The Challenge of PSC Clinical Trials: When “Success” No Longer Simply Means Waiting for Liver Failure
Primary sclerosing cholangitis progresses slowly and brutally, and traditional hard endpoints often make trials long, expensive, and difficult to conduct; how endpoints are being redefined is affecting whether new drugs can truly reach patients.